Anticoagulants, Retinoids and Immunosuppressants Before a Needle

Three Mechanisms, Not Thirty Drugs

A studio cannot memorise a formulary and does not need to. Almost every medication that matters at intake acts through one of three routes. The first is haemostasis. Anticoagulants and antiplatelet drugs interrupt the clotting cascade or stop platelets aggregating. The consequence at the needle is prolonged oozing rather than dramatic bleeding, and the practical cost is ink that will not settle and a piercing channel that fills with blood before it can close. The second is epidermal repair. Systemic retinoids change how fast the epidermis turns over and how much sebum the skin produces. This is the group that produces genuinely bad outcomes rather than merely messy ones. The third is immune response. Methotrexate, biologic agents and calcineurin inhibitors suppress exactly the inflammatory response a fresh wound depends on. The risk is infection and delayed closure, and it is the group where a specialist's clearance matters most. Most of what else appears on a client's list is irrelevant to the procedure. Ask which of the three a drug belongs to and the conversation becomes short.

Anticoagulants and Antiplatelets: Oozing, Not Haemorrhage

This is the largest group and the most misunderstood. Warfarin, the direct oral anticoagulants, the P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) and low-molecular-weight heparin all raise bleeding at a skin-breaking procedure. Dermatologic surgery has studied this properly and the consensus is consistent: for minor cutaneous procedures the bleeding is manageable and the drugs are not stopped [1][3]. That matters because the instinct in a studio runs backwards. The temptation is to ask the client to skip a dose. The literature says the opposite - the thrombotic risk of interrupting therapy outweighs the bleeding risk of continuing it, and a systematic review of minimal-bleeding-risk procedures found continuous direct oral anticoagulant use acceptable rather than requiring interruption [2]. The dental literature reaches the same conclusion for a comparable minor procedure [4]. At the chair this means a client on anticoagulation is not automatically refused, but the session will bleed more, ink saturation will suffer and a piercing will take longer to settle. Those are quality and expectation problems, not safety emergencies. The safety line sits elsewhere: never advise a pause. If one is appropriate, only the prescriber can say so, and clopidogrel in particular is often prescribed after a cardiac stent where stopping carries real danger.

Isotretinoin: The One Real Contraindication

Isotretinoin is the drug on this page that most deserves a firm no. It alters epidermal cell turnover, thins the skin and suppresses sebum production. The concern for procedures during and shortly after treatment is impaired healing and abnormal scarring, and a 2026 review examining the safety of dermatological and surgical procedures during systemic isotretinoin is the current reference point [5]. Conventional professional guidance is a wait of 6 to 12 months after the course finishes. It is worth saying plainly where that figure comes from: three small case series from the 1980s. A 2017 systematic review with consensus recommendations found no good evidence for delaying most superficial skin procedures, including cutaneous surgery and laser hair removal, while advising against mechanical dermabrasion and fully ablative laser [10]. Tattooing and piercing were not studied. The studio wait is therefore precautionary and errs wide, because the failure mode is a permanent scar through work the client paid for. A piercing during treatment faces the same problem from the other direction. Fragile skin that heals slowly does not form a stable fistula, and the outcome is hypertrophic scarring or outright rejection.

Immunosuppressants: Infection, and Who Decides

Methotrexate, TNF inhibitors and other biologic agents, and calcineurin inhibitors all suppress parts of the immune response. A fresh tattoo or piercing is an open wound maintained for weeks, so the concern is bacterial infection and delayed closure rather than anything to do with the ink. One caveat belongs in the open, because it changes how the sources should be read. The perioperative literature on biologics and DMARDs is largely orthopaedic and rheumatological - joint replacement, not body art [6][7]. The mechanism transfers; the specific figures do not. Those sources establish that the concern is real. They do not quantify it for a piercing. The practical rule is the same across the group, and it is not the studio's call. Do not ask a client to interrupt a biologic. Scheduling relative to an injection cycle is a reasonable conversation for the client to have with their specialist, and the studio's job is to require that the conversation happened, not to design the timing.

Opioids: A Consent and Syncope Problem

Opioids belong on this page for a different reason from everything above. They do not meaningfully change how a tattoo heals. They change what happens during the session. The documented risk is vasovagal syncope - fainting - in a conscious person undergoing a painful needle procedure, alongside sedation, lowered blood pressure and nausea. The closest studied analogue is dentistry, where syncope risk factors and prevention during minor procedures are well described [9]. A tattoo chair and a dental chair pose the same problem: a conscious patient, a needle, and procedural pain. There is a second issue that is not clinical at all. Someone acutely under the influence of high-dose narcotics cannot give informed consent, and a studio that proceeds anyway has a problem no aftercare sheet will fix. Decline and rebook. Chronic prescribed pain medication is a different situation from acute intoxication, and is a matter for the client's prescriber rather than an automatic refusal. One practical note from the floor, which applies to any client at risk of fainting and not only to opioids. Experienced piercers learn to spot the people prone to it, and the cheap intervention is to send them out for a chocolate bar or something sugary, have them eat it, and then proceed. The second is about the room rather than the client: allow one companion at most, and have that person sit down. A relative who wants to watch and then faints turns one manageable situation into two.

Topical Anaesthetics: The Rebound Nobody Plans For

Numbing preparations containing epinephrine constrict blood vessels, which is exactly why they appear to work well early in a session. When the vasoconstriction wears off, rebound hyperaemia follows: rapid vascular dilation, intense bleeding and heavy plasma exudate at precisely the point when fresh ink is trying to settle. There is a second risk a studio is poorly placed to judge. Systemic absorption rises sharply on compromised skin, and a 2025 review of the systemic risks of topical anaesthetics in barrier-compromised patients is the reference for that concern [8]. The case to worry about is client-applied high-concentration cream, because dose, area and occlusion are all unknown to you. This page covers the interaction only; the full pharmacology of lidocaine, prilocaine and tetracaine has its own reference.

Medication Intake Protocol

The whole page reduces to a short intake sequence. It takes under a minute of actual questions, though the conversation around it should take considerably longer. One principle governs the rest, and most studios have it backwards. Universal precautions are not a fallback for the client who does not disclose - they ARE the procedure. Cross-contamination control that only works when someone tells you the truth is not control at all, and any working piercer has unknowingly worked on people with a bloodborne condition. So a disclosed condition should never change your technique. What it changes is the advice you can give, and whether you proceed at all. Expect the conversation to change decisions, and treat that as the point rather than as lost work. In Patrick's studio roughly one client in five either stepped back or moved the appointment once they understood what was actually involved - a holiday that made proper aftercare impossible, a job where a fresh piercing was an extra burden and risk, the longer labret that has to stick out for weeks to allow for swelling, or an admission of alcohol or drugs in the previous two days. A studio whose consultations never change anyone's mind is not screening; it is processing.

1. 1Ask an open question, not a tick box. "What do you take?" surfaces answers that "Do you have any medical conditions?" never will - someone on a statin and a blood thinner does not consider themselves ill.
2. 2Name supplements explicitly. Fish oil, garlic, ginkgo, vitamin E, high-dose vitamin C. Clients do not classify these as medication and will not mention them unprompted.
3. 3Ask about the last 24 hours. Alcohol and recreational drugs matter for consent and for staying still, and the question lands easily in a friendly conversation and badly on a form.
4. 4Sort what you hear into the three mechanisms: bleeding, healing, or immune. Anything outside those three is usually not your concern.
5. 5Never advise stopping or pausing a prescribed drug. This is the one rule on this page with no exceptions.
6. 6Where the risk warrants it, ask for written clearance from the prescriber rather than a verbal assurance. A client who takes the time to come back with a letter has told you something about how they will handle aftercare too.
7. 7Adjust expectations instead of refusing by default. A client on anticoagulation can usually be worked on if both sides accept that saturation will suffer and healing will run long.
8. 8Refuse where refusing is genuinely correct: isotretinoin inside the wait window, and acute intoxication of any kind.
9. 9Close by handing the decision back: "So now you know what is involved, do you still want me to do this, or do you want time to think about it and come back another day?" Ask it only when you are already confident the answer should be yes.
10. 10Record that the question was asked and what was done about the answer.

Common Errors and Failure Modes

Each of these is something we have seen go wrong, and each has a straightforward correction.

• ⚠️Telling a client to skip a dose. It comes from a good place and it is the most dangerous thing a studio can do. Refusing a session is always available to you; adjusting someone's cardiac medication never is.
• ⚠️Asking about conditions instead of drugs. A tick box marked "any medical conditions" returns almost nothing useful, because most people on long-term medication do not think of themselves as having a condition.
• ⚠️Treating supplements as harmless. The client on warfarin who also takes garlic capsules is compounding an effect that has published human studies behind it, and will not mention it unless asked by name.
• ⚠️Refusing anticoagulated clients outright. The dermatologic evidence does not support blanket refusal; it supports adjusted expectations and a clear conversation about saturation and healing time.
• ⚠️Accepting a verbal "my doctor says it's fine". Where the risk is real, ask for it in writing. This is as much for the client's protection as the studio's.
• ⚠️Treating chronic prescribed opioids as equivalent to acute intoxication. They are different situations - one is a prescriber conversation, the other is a decline on the day.
• ⚠️Quoting a mechanism because it sounds right. Three widely repeated claims on this page have no evidence behind them. Saying "we don't know" costs a studio nothing and is far better than being wrong in front of a client who checks.

Regulatory Framework by Jurisdiction

Medication sits outside the studio's legal competence in every jurisdiction on this page. The regulatory question is not whether a drug is restricted, it is who is authorised to advise on it. Everywhere below that person is the prescriber. The studio's lawful interest is narrower and more useful: screening, documentation, informed consent, and a decision about whether to proceed today.

Related Topics

Wound healing biology explains the repair sequence these drugs interfere with. Keloid and hypertrophic scarring covers the outcome isotretinoin risks. Infection triage and microbiology covers recognising the infections immunosuppression makes more likely. Topical anaesthetics pharmacology covers numbing preparations in full.